A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion

Abstract

Background. Proper diagnosis of pancreatic lesion etiology is a challenging clinical dilemma. Studies suggest that surgery for suspected pancreatic ductal adenocarcinoma (PDAC) reveals a benign lesion in 5% to 13% of cases. The aim of our study was to assess whether routinely used biomarkers such as CA19-9, Ca125, Ca15-3, and CEA, when combined, can potentially yield an accurate test predicting pancreatic lesion etiology. Methods. We retrospectively analyzed data of 326 patients who underwent a diagnostic process due to pancreatic lesions of unknown etiology. Results. We found statistically significant differences in mean levels of all biomarkers. In logistic regression model, we applied levels CA19-9, Ca125, and Ca15-3 as variables. Two validation methods were used, namely, random data split into training and validation groups and bootstrapping. Afterward, we built ROC curve using the model that we had created, reaching AUC = 0,801. With an optimal cut-off point, it achieved specificity of 81,2% and sensitivity of 63,10%. Our proposed model has superior diagnostic accuracy to both CA19-9 (p = 0,0194) and CA125 (p = 0,0026). Conclusion. We propose a test that is superior to CA19-9 in a differential diagnosis of pancreatic lesion etiology. Although our test fails to reach exceptionally high accuracy, its feasibility and cost-effectiveness make it clinically useful.

Purity of islet preparations and 5-year metabolic outcome of allogenic islet transplantation

“…Several mechanisms such as alterations of exocrine pancreas depending on the duration of T1D and exposure to autoantibody levels may contribute to increased CA19-9. 23 Furthermore, it must be noted that CA19-9 levels were not directly correlated with metabolic results. This marginal difference appeared related to a higher level of CA19-9 in some IAK patients in the LOW purity group before IT.…”

“…In addition, the recognition of the expected increase of this marker may obviate the need for repeat morphological investigations seeking pancreatic or digestive cancer in IT patients with high CA19-9 level. 23 Furthermore, it must be noted that CA19-9 levels were not directly correlated with metabolic results. This point raises questions on the mechanisms linking preparation purity (correlated to CA19-9 levels) with better long-term metabolic outcomes in the LOW purity group.…”

Detection of Epithelial Ovarian Cancer using C8Magnetic Bead Separation and MALDI-TOF Plasma Proteome Profiling in Egyptian Females

“…Gynecologic cancers constitute a major health burden in Egypt. Ovarian cancer is the 4 th commonest cancer among Egyptian females (Ibrahim et al, 2014). It has the highest mortality rate of all gynecological cancers (Ferlay et al, 2015).…”

“…It is also used for monitoring the response to treatment, follow-up of the disease, and detection of disease recurrence. However, this tumor marker can be increased in several gynecological and non-gynecological diseases, and this reduces the diagnostic accuracy for the detection of ovarian cancer (Hogendorf et al, 2017).…”

Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?

“…It is also used for monitoring the response to treatment, follow-up of the disease, and detection of disease recurrence [ 7 ]. This tumor marker can be increased in several gynecological and nongynecological diseases, and this reduces the diagnostic accuracy for the detection of ovarian cancer [ 8 – 11 ].…”